Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1991 2
1992 1
1993 1
1994 1
1995 2
1996 3
1997 5
1998 3
1999 3
2000 1
2001 2
2002 4
2003 9
2004 4
2005 2
2006 8
2007 6
2008 5
2009 7
2010 11
2011 8
2012 10
2013 3
2014 3
2015 7
2016 6
2017 1
2018 3
2019 9
2020 3
2021 1
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Results by year

Filters applied: . Clear all
Page 1
Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions.
Monk BJ, Tewari KS, Koh WJ. Monk BJ, et al. J Clin Oncol. 2007 Jul 10;25(20):2952-65. doi: 10.1200/JCO.2007.10.8324. J Clin Oncol. 2007. PMID: 17617527 Review.
In 1999, weekly intravenous cisplatin at 40 mg/m2 for 6 weeks in combination with RT was established as a new standard for the treatment of locally advanced cervical carcinoma. More recently, this recommendation has been expanded to include women with …
In 1999, weekly intravenous cisplatin at 40 mg/m2 for 6 weeks in combination with RT was established as a new standard for the treatment of …
Modern management of locally advanced cervical carcinoma.
Dueñas-Gonzalez A, Cetina L, Mariscal I, de la Garza J. Dueñas-Gonzalez A, et al. Cancer Treat Rev. 2003 Oct;29(5):389-99. doi: 10.1016/s0305-7372(03)00068-9. Cancer Treat Rev. 2003. PMID: 12972357 Review.
Radiation was until recently the key and only modality for the routine treatment of locally advanced cervical carcinoma. However after years of studying multi-modality treatments as an alternative to radiation alone in randomized phase III trials, the …
Radiation was until recently the key and only modality for the routine treatment of locally advanced cervical carcin …
Neoadjuvant Chemotherapy in Locally Advanced Cervical Carcinoma - a Role in Patients with Para-aortic Lymph Node Involvement? A 10-year Institutional Experience.
Green HM, Counsell N, Ward A, McCormack M. Green HM, et al. Clin Oncol (R Coll Radiol). 2022 Jul;34(7):e281-e290. doi: 10.1016/j.clon.2021.12.005. Epub 2022 Jan 6. Clin Oncol (R Coll Radiol). 2022. PMID: 35000828
AIMS: Overall survival and progression-free survival with concomitant chemoradiotherapy for locally advanced cervical carcinoma have been described as 66% and 58%, respectively, at 5 years. ...
AIMS: Overall survival and progression-free survival with concomitant chemoradiotherapy for locally advanced cervical …
Mind the Gap Between Scientific Literature Recommendations and Effective Implementation. Is There Still a Role for Surgery in the Treatment of Locally Advanced Cervical Carcinoma?
Blidaru A, Bordea C, Burcoş T, Duduş L, Eniu D, Ioanid N, Kacso G, Minciuna C, Savu M, Scripcariu V, Tudor Ș, Vasilescu C, Voinea S. Blidaru A, et al. Chirurgia (Bucur). 2019 Jan-Feb;114(1):18-28. doi: 10.21614/chirurgia.114.1.18. Chirurgia (Bucur). 2019. PMID: 30830841 Free article. Review.
Tumor histology is an independent prognostic factor in locally advanced cervical carcinoma: A retrospective study.
Gallardo-Alvarado L, Cantú-de León D, Ramirez-Morales R, Santiago-Concha G, Barquet-Muñoz S, Salcedo-Hernandez R, Reyes C, Perez-Alvarez S, Perez-Montiel D, Perez-Plasencia C, Trejo-Duran E, Galicia JP. Gallardo-Alvarado L, et al. BMC Cancer. 2022 Apr 13;22(1):401. doi: 10.1186/s12885-022-09506-3. BMC Cancer. 2022. PMID: 35418030 Free PMC article.
The aim of this study was to evaluate tumor histology as a prognostic factor in terms of treatment outcomes, disease-free survival (DFS) and overall survival (OS) in a retrospective cohort of patients with Locally Advanced Cervical Carcinoma (LACC). ME …
The aim of this study was to evaluate tumor histology as a prognostic factor in terms of treatment outcomes, disease-free survival (DFS) and …
Combined use of hyperthermia and radiation therapy for treating locally advanced cervical carcinoma.
Lutgens L, van der Zee J, Pijls-Johannesma M, De Haas-Kock DF, Buijsen J, Mastrigt GA, Lammering G, De Ruysscher DK, Lambin P. Lutgens L, et al. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD006377. doi: 10.1002/14651858.CD006377.pub2. Cochrane Database Syst Rev. 2010. PMID: 20091593 Review.
Because large scale randomised clinical trials (RCTs) are lacking, firm conclusions cannot be drawn regarding its definitive role as an adjunct to radiotherapy in the treatment of locally advanced cervical carcinoma (LACC). OBJECTIVES: To assess whethe …
Because large scale randomised clinical trials (RCTs) are lacking, firm conclusions cannot be drawn regarding its definitive role as an adju …
Laparoscopic paraaortic surgical staging in locally advanced cervical cancer: a single-center experience.
Vázquez-Vicente D, Fernández Del Bas B, García Villayzán J, Di Fiore HA, Luna Tirado J, Casado Echarren V, García-Foncillas J, Plaza Arranz J, Chiva L. Vázquez-Vicente D, et al. Clin Transl Oncol. 2018 Nov;20(11):1455-1459. doi: 10.1007/s12094-018-1878-4. Epub 2018 Apr 18. Clin Transl Oncol. 2018. PMID: 29671223
BACKGROUND: One aim of this study was to assess the efficacy and safety of laparoscopic paraaortic lymphadenectomy for paraaortic lymph node staging in locally advanced cervical carcinoma. The second aim was to identify prognostic factors in the evolut …
BACKGROUND: One aim of this study was to assess the efficacy and safety of laparoscopic paraaortic lymphadenectomy for paraaortic lymph node …
Locally advanced cervical carcinoma patients treated with chemoradiation followed by radical surgery: clinical response and oncological outcomes according to histotype after propensity score analysis.
Legge F, Bizzarri N, Gallotta V, Pedone Anchora L, Cosentino F, Turco LC, Certelli C, Macchia G, Valentini V, Scambia G, Ferrandina G. Legge F, et al. Eur J Surg Oncol. 2022 Sep;48(9):2045-2052. doi: 10.1016/j.ejso.2022.04.004. Epub 2022 Apr 12. Eur J Surg Oncol. 2022. PMID: 35450757
126 results